Cost-effectiveness of systematic chemotherapy for metastatic pancreatic cancer: a retrospective study using Japanese clinical data
Abstract We compared the cost-effectiveness of gemcitabine plus nab-paclitaxel (GnP) and modified FOLFIRINOX (mFFX)—standard first-line treatments for metastatic pancreatic cancer in Japan. This retrospective cohort study included patients with metastatic pancreatic cancer treated at the National Ca...
Saved in:
Main Authors: | Akira Shinohara, Yuki Takumoto, Junko Tauchi, Koki Morishita, Toshikatsu Kawasaki, Manabu Akazawa |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-024-80549-1 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Survival benefits of adjuvant chemotherapy after conversion surgery in patients with advanced pancreatic cancer
by: Yoon Suk Lee, et al.
Published: (2025-01-01) -
Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2
by: Hemant M. Kocher, et al.
Published: (2025-01-01) -
Metastatic pancreatic cancer now in remission: a case report and literature review
by: Charles W. Shi, et al.
Published: (2025-01-01) -
Global metabolomic profiling of tumor tissue and paired serum samples to identify biomarkers for response to neoadjuvant FOLFIRINOX treatment of human pancreatic cancer
by: Manoj Amrutkar, et al.
Published: (2025-02-01) -
Epithelial–Mesenchymal Transition Suppression by ML210 Enhances Gemcitabine Anti-Tumor Effects on PDAC Cells
by: Keisuke Takemura, et al.
Published: (2025-01-01)